Eli Lilly lifts 2026 guidance on robust Q2, pipeline momentum and manufacturing expansion
Aug 5, 2026, 6:47 AM EDT3 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The beat-and-raise earnings narrative, combined with expanding Mounjaro/Zepbound franchises and multiple regulatory milestones, typically prompts short-term upside. However, elevated IPR&D charges temper GAAP earnings, so the upside may be moderated by profit-quality concerns and optics around acquisitions. Historically, Lilly has shown stock moves on strong guidance and pipeline news, supporting a near-term rally.
AI summary
What happened, with direct paths to the underlying reporting
Eli Lilly delivered a strong Q2 2026, with revenue of $23.0B (+48% YoY) driven by Mounjaro and Zepbound, and both GAAP and non-GAAP EPS beating prior guidance. The company raised 2026 revenue guidance to $85–$87B and non-GAAP EPS to $35.50–$36.50, partially offset by $3.03B in acquired IPR&D charges. Regulatory and pipeline progress, plus aggressive manufacturing expansion, position Lilly for continued growth into 2027.
Q2 2026 revenue $23.0B, up 48% YoY, led by Mounjaro/Zepbound.
2026 revenue guidance raised to $85–$87B; non-GAAP EPS $35.50–$36.50.
Regulatory progress: CHMP recommends Jaypirca; FDA approves EBGLYSS (lebrikizumab) for AD.
Mounjaro $9.9B globally; Zepbound US $4.9B; Indiana capex $4.5B expansion.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Gate Bioscience expanded its research and licensing agreement with Eli Lilly to develop treatments targeting disease-causing proteins, potentially worth more than $870 million. Th…
Amylin-targeting eloralintide, paired with tirzepatide, produced notable Phase 2 weight-loss results, including 23.3% loss at 48 weeks in the high-dose combo. Standalone and combi…
Novo Nordisk reports a real-world study suggesting escalated Ozempic doses may reduce major cardiovascular events versus Lilly's Mounjaro. If validated, the finding could tilt phy…
Eli Lilly reports an indirect analysis indicating Foundayo 17.2 mg achieves greater weight loss and A1C reduction versus oral semaglutide 25 mg at 52 weeks, based on ACHIEVE-3 and…
